Quinidine sulfate administration for intractable epilepsy with KCNT1 gene mutation

Quinidine sulfate administration for intractable epilepsy with KCNT1 gene mutation - Quinidine sulfate administration for intractable epilepsy with KCNT1 gene mutation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019594

Enrollment

Registered

2015-11-02

Start date

2015-11-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intractable epilepsy with KCNT1 gene mutation

Interventions

Quinidine sulfate administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of intractable epilepsy with KCNT1 gene mutation

Exclusion criteria

Exclusion criteria: The patient who is judged by the patient's physician as unsuitable for participating in this study.

Design outcomes

Primary

Measure	Time frame
Change in frequency of epileptic seizures	—

Secondary

Measure	Time frame
Change in severity of epileptic seizures. Change in EEG finding. Change in psychomotor development.	—

Countries

Japan

Contacts

Public ContactKatsumi IMAI

NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders Department of Epileptology

imaik-1@hosp.go.jp054-245-5446

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026